Minimal Invasive Hysteroscopy for Anomal Uterine Hemorrhages: Personalized Approach Based on 3d Ultrason and Endometric Profilization
DOI:
https://doi.org/10.31149/ijimm.v4i4.2850Keywords:
Abnormal Uterine Bleeding, Hysteroscopy, Minimally Invasive Surgery, Three-Dimensional Ultrasound Examination, 3D Ultrasound, Endometrial Profiling, Molecular Endometrial Testing, Personalized Medicine, EchographyAbstract
Abnormal uterine bleeding (ABB) occupies a leading position in the structure of gynecological morbidity. Despite the widespread use of hysteroscopy, the frequency of relapses and repeated interventions remains significant. Personalization of surgical tactics based on 3D transvaginal ultrasound and endometrial immunohistochemical profile can potentially increase the clinical effectiveness of treatment.
References
[1] M. G. Munro, H. O. D. Critchley, M. S. Broder, and I. S. Fraser, “FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in non-pregnant women of reproductive age,” International Journal of Gynecology & Obstetrics, vol. 113, pp. 3–13, 2011.
[2] L. D. Bradley, “Overview of hysteroscopy in abnormal uterine bleeding,” Clinical Obstetrics and Gynecology, vol. 58, pp. 145–159, 2015.
[3] S. Bettocchi, L. Nappi, O. Ceci, and L. Selvaggi, “Office hysteroscopy,” Obstetrics and Gynecology Clinics of North America, vol. 31, pp. 641–654, 2004.
[4] R. Salim, B. Woelfer, M. Backos, L. Regan, and D. Jurkovic, “Reproducibility of three-dimensional ultrasound diagnosis of congenital uterine anomalies,” Ultrasound in Obstetrics & Gynecology, vol. 21, no. 6, pp. 578–582, 2003.
[5] M. Dueholm and I. M. D. Hjorth, “Structured imaging technique in the gynecological office for the diagnosis of abnormal uterine bleeding,” Best Practice & Research Clinical Obstetrics & Gynaecology, vol. 40, pp. 23–43, 2017.
[6] C. L. Trimble et al., “Concomitant endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia,” Cancer, vol. 106, pp. 812–819, 2006.
[7] S. D. Reed et al., “Incidence of endometrial hyperplasia,” American Journal of Obstetrics and Gynecology, vol. 200, pp. 678.e1–678.e6, 2009.
[8] A. Vitagliano et al., “Effects of chronic endometritis therapy on reproductive outcome,” Fertility and Sterility, vol. 110, pp. 103–112, 2018.
[9] T. J. Clark et al., “Endometrial biopsy in abnormal uterine bleeding: diagnostic accuracy,” BJOG, vol. 118, no. 8, pp. 899–907, 2011.
[10] ACOG, “Practice Bulletin No. 128: Diagnosis of abnormal uterine bleeding in women of reproductive age,” Obstetrics and Gynecology, vol. 120, pp. 197–206, 2012.
[11] E. Dreisler, S. S. Sorensen, P. H. Ibsen, and G. Lose, “Preoperative ultrasound in hysteroscopic surgery,” Acta Obstetricia et Gynecologica Scandinavica, vol. 88, no. 10, pp. 1136–1141, 2009.
[12] I. D. Gallos et al., “Regression, relapse, and live birth rates with fertility-saving therapy for endometrial hyperplasia,” American Journal of Obstetrics and Gynecology, vol. 203, pp. 547.e1–547.e10, 2010.
[13] H. O. D. Critchley and M. G. Munro, “Abnormal uterine bleeding: management and classification,” The Lancet, vol. 393, no. 10185, pp. 1312–1323, 2019.
[14] National Institute for Health and Care Excellence (NICE), Heavy menstrual bleeding: assessment and management, London, UK, 2018.
[15] World Health Organization, WHO recommendations for the management of abnormal uterine bleeding, Geneva, Switzerland: WHO, 2021.
